benzyl 2-naphthyl ether has been researched along with yohimbine in 1 studies
Studies (benzyl 2-naphthyl ether) | Trials (benzyl 2-naphthyl ether) | Recent Studies (post-2010) (benzyl 2-naphthyl ether) | Studies (yohimbine) | Trials (yohimbine) | Recent Studies (post-2010) (yohimbine) |
---|---|---|---|---|---|
5 | 0 | 2 | 5,893 | 253 | 532 |
Protein | Taxonomy | benzyl 2-naphthyl ether (IC50) | yohimbine (IC50) |
---|---|---|---|
Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.0353 | |
Cytochrome P450 2D6 | Homo sapiens (human) | 1.02 | |
D(2) dopamine receptor | Homo sapiens (human) | 2.06 | |
Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 1.3 | |
Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.0428 | |
Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.0466 | |
5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.126 | |
Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0682 | |
Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0682 | |
Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0682 | |
Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 1.3 | |
Alpha-1D adrenergic receptor | Homo sapiens (human) | 1.013 | |
5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.126 | |
5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.074 | |
Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 1.3 | |
5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 1.689 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Kumar, K; Lachance, H; Waldmann, H; Wetzel, S | 1 |
1 review(s) available for benzyl 2-naphthyl ether and yohimbine
Article | Year |
---|---|
Charting, navigating, and populating natural product chemical space for drug discovery.
Topics: Biological Products; Databases, Factual; Drug Design; Drug Discovery; Drug Industry; Models, Molecular; Molecular Structure; Principal Component Analysis; Small Molecule Libraries; Structure-Activity Relationship | 2012 |